Menu
Our Geno1™ technology enables unprecedented advantages in the domain of liquid biopsies and beyond, by reducing costs and thus making next-generation diagnostic solutions accessible for any and all patients.
Liquid biopsies are part of a growing megatrend in cancer diagnostics, permitting non-invasive precision diagnostics and early detection of cancer. These novel diagnostic and therapeutic solutions are increasingly important in our aging societies. However, they are still non-accessible for the big majority of patients and there is room for improvement.
Our Geno1™ technology derives from world class academic research conducted at MIT in US and ETH Zurich in Switzerland, latter generously supported by Bill & Melinda Gates Foundation
The technology truly enables unprecedented scaling of liquid biopsies and beyond, by tackling the three main drivers: cost, accuracy and turn-around-time.
